Treating the elderly diabetic patient: special considerations

References

• Centers for Disease Control and Prevention 2011 National Diabetes Fact Sheet Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf Accessed January 20, 2014
   Google Scholar
• Cowie CC Rust KF Ford ES Full accounting of diabetes and pre-diabetes in the US population in 1988–1994 and 2005–2006 Diabetes Care 2009 32 287 294 19017771
   PubMed Web of Science ®Google Scholar
• Fox CS Pencina MJ Meigs JB Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study Circulation 2006 113 25 2914 2918 16785337
   PubMed Web of Science ®Google Scholar
• Sue Kirkman M Briscoe VJ Clark N Diabetes in older adults: a consensus report J Am Geriatr Soc 2012 60 12 2342 2356 23106132
   PubMed Web of Science ®Google Scholar
• Bethel MA Sloan FA Belsky D Feinglos MN Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients Arch Intern Med 2007 167 9 921 927 17502533
   PubMedGoogle Scholar
• No authors listed Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998 352 9131 837 853 9742976
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group Patel A MacMahon S Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 358 24 2560 2572 18539916
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group Gerstein HC Miller ME Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 24 2545 2559 18539917
   PubMed Web of Science ®Google Scholar
• Duckworth W Abraira C Moritz T Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 2009 360 2 129 139 19092145
   PubMed Web of Science ®Google Scholar
• Currie CJ Peters JR Tynan A Survival as a function of HbA(1c) in people with type 2 diabetes: A retrospective cohort study Lancet 2010 375 9713 481 489 20110121
   PubMed Web of Science ®Google Scholar
• Huang ES Liu JY Moffet HH Glycemic control, complications, and death in older diabetic patients: The Diabetes and Aging Study Diabetes Care 2011 34 6 1329 1336 21505211
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes – 2013 Diabetes Care 2013 36 Suppl 1 S11 S66 23264422
   PubMed Web of Science ®Google Scholar
• Sinclair AJ Paolisso G Castro M European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary Diabetes Metab 2011 37 Suppl 3 S27 S38 22183418
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2006 29 8 1963 1972 16873813
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Bantle JP Wylie-Rosett J Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association Diabetes Care 2008 31 Suppl 1 S61 S78 18165339
   PubMed Web of Science ®Google Scholar
• Miller CK Edwards L Kissling G Sanville L Nutrition education improves metabolic outcomes among older adults with diabetes mellitus: results from a randomized controlled trial Prev Med 2002 34 2 252 259 11817922
   PubMed Web of Science ®Google Scholar
• Sigal RJ Kenny GP Wasserman DH Castaneda-Sceppa C Physical activity/exercise and type 2 diabetes Diabetes Care 2004 27 10 2518 2539 15451933
   PubMed Web of Science ®Google Scholar
• Lindeman RD Tobin J Shock NW Longitudinal studies on the rate of decline in renal function with age J Am Geriatr Soc 1985 33 4 278 285 3989190
   PubMed Web of Science ®Google Scholar
• O’Malley K Crooks J Duke E Stevenson IH Effect of age and sex on human drug metabolism Br Med J 1971 3 5775 607 609 5569980
   PubMed Web of Science ®Google Scholar
• Turnheim K Drug dosage in the elderly. Is it rational? Drugs Aging 1998 13 5 357 379 9829164
   PubMed Web of Science ®Google Scholar
• Fravel MA McDanel DL Ross MB Special considerations for treatment of type 2 diabetes mellitus in the elderly Am J Health Sys Pharm 2011 68 6 500 509
   PubMed Web of Science ®Google Scholar
• Bailey CJ Biguanides and NIDDM Diabetes Care 1992 15 6 755 772 1600835
   PubMed Web of Science ®Google Scholar
• Bailey CJ Turner RC Metformin N Engl J Med 1996 334 9 574 579 8569826
   PubMed Web of Science ®Google Scholar
• Stumvoll M Nurjhan N Perriello G Metabolic effects of metformin in non-insulin-dependent diabetes mellitus N Engl J Med 1995 333 9 550 554 7623903
   PubMed Web of Science ®Google Scholar
• No authors listed United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years BMJ 1995 310 6972 83 88 7833731
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Goodman AM Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group N Engl J Med 1995 333 9 541 549 7623902
   PubMed Web of Science ®Google Scholar
• Saenz A Fernandez-Esteban I Mataix A Metformin monotherapy for type 2 diabetes mellitus Cochrane Database Syst Rev 2005 3 CD002966 16034881
   PubMed Web of Science ®Google Scholar
• Setter SM Iltz JL Thams J Campbell RK Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy Clin Ther 2003 25 12 2991 3026 14749143
   PubMed Web of Science ®Google Scholar
• de Jager J Kooy A Lehert P Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial BMJ 2010 340 c2181 20488910
   PubMed Web of Science ®Google Scholar
• Stang M Wysowski DK Butler-Jones D Incidence of lactic acidosis in metformin users Diabetes Care 1999 22 6 925 927 10372243
   PubMed Web of Science ®Google Scholar
• Salpeter SR Greyber E Pasternak GA Salpeter EE Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Cochrane Database Syst Rev 2010 4 CD002967
   Web of Science ®Google Scholar
• Sirtori CR Pasik C Re-evaluation of a biguanide, metformin: mechanism of action and tolerability Pharmacol Res 1994 30 3 187 228 7862618
   PubMed Web of Science ®Google Scholar
• Shaw JS Wilmot RL Kilpatrick ES Establishing pragmatic estimated GFR thresholds to guide metformin prescribing Diabet Med 2007 24 10 1160 1163 17672860
   PubMed Web of Science ®Google Scholar
• Warren RE Strachan MW Wild S McKnight JA Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin Diabet Med 2007 24 5 494 497 17367305
   PubMed Web of Science ®Google Scholar
• Hermann LS Scherstén B Bitzén PO Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study Diabetes Care 1994 17 10 1100 1109 7821128
   PubMed Web of Science ®Google Scholar
• Bressler R Johnson DG Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus Arch Intern Med 1997 157 8 836 848 9129543
   PubMedGoogle Scholar
• Neumiller JJ Setter SM Pharmacologic management of the older patient with type 2 diabetes mellitus Am J Geriatr Pharmacother 2009 7 6 324 342 20129254
   PubMedGoogle Scholar
• Shorr RI Ray WA Daugherty JR Griffin MR Individual sulfonylureas and serious hypoglycemia in older people J Am Geriatr Soc 1996 44 7 751 755 8675920
   PubMed Web of Science ®Google Scholar
• Shorr RI Ray WA Daugherty JR Griffin MR Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas Arch Intern Med 1997 157 15 1681 1686 9250229
   PubMed Web of Science ®Google Scholar
• No authors listed A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide Diabetes 1976 25 12 1129 1153 992232
   PubMed Web of Science ®Google Scholar
• Garratt KN Brady PA Hassinger NL Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction J Am Coll Cardiol 1999 33 1 119 124 9935017
   PubMed Web of Science ®Google Scholar
• Malmberg K Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group BMJ 1997 314 7093 1512 1515 9169397
   PubMed Web of Science ®Google Scholar
• Simpson SH Majumdar SR Tsuyuki RT Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study CMAJ 2006 174 2 169 174 16415461
   PubMed Web of Science ®Google Scholar
• Roumie CL Hung AM Greevy RA Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study Ann Intern Med 2012 157 6 601 610 23128859
   PubMed Web of Science ®Google Scholar
• Stevens RJ Coleman RL Adler AI Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66 Diabetes Care 2004 27 1 201 207 14693990
   PubMed Web of Science ®Google Scholar
• Hemmingsen B Schroll JB Lund SS Sulphonylurea monotherapy for patients with type 2 diabetes mellitus Cochrane Database Syst Rev 2013 4 CD009008 23633364
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BH Landgraf R A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group Diabetes Care 1999 22 3 463 467 10097930
   PubMed Web of Science ®Google Scholar
• Prandin (repaglinide) tablets (05, 1 and 2 mg) [prescribing information] Princeton, NJ Novo Nordisk Inc 2010
   Google Scholar
• Yki-Järvinen H Thiazolidinediones N Engl J Med 2004 351 11 1106 1118 15356308
   PubMed Web of Science ®Google Scholar
• Grey A Skeletal consequences of thiazolidinedione therapy Osteoporos Int 2008 19 2 129 137 17901911
   PubMed Web of Science ®Google Scholar
• Colmers IN Bowker SL Majumdar SR Johnson JA Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis CMAJ 2012 184 12 E675 E683 22761478
   PubMed Web of Science ®Google Scholar
• Lipscombe LL Gomes T Lévesque LE Thiazolidinediones and cardiovascular outcomes in older patients with diabetes JAMA 2007 298 22 2634 2643 18073359
   PubMed Web of Science ®Google Scholar
• Winkelmayer WC Setoguchi S Levin R Solomon DH Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy Arch Intern Med 2008 168 21 2368 2375 19029503
   PubMed Web of Science ®Google Scholar
• Juurlink DN Gomes T Lipscombe LL Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study BMJ 2009 339 b2942 19690342
   PubMed Web of Science ®Google Scholar
• Graham DJ Ouellet-Hellstrom R MaCurdy TE Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone JAMA 2010 304 4 411 418 20584880
   PubMed Web of Science ®Google Scholar
• Home PD Pocock SJ Beck-Nielsen H Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 2009 373 9681 2125 2135 19501900
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [homepage on the Internet] FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines Available from: http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm Assessed May 10, 2014
   Google Scholar
• Schwartz AV Sellmeyer DE Vittinghoff E Thiazolidinedione use and bone loss in older diabetic adults J Clin Endocrinol Metab 2006 91 9 3349 3354 16608888
   PubMed Web of Science ®Google Scholar
• Habib ZA Havstad SL Wells K Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus J Clin Endocrinol Metab 2010 95 2 592 600 20061432
   PubMed Web of Science ®Google Scholar
• van de Laar FA Lucassen PL Akkermans RP Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis Diabetes Care 2005 28 1 154 163 15616251
   PubMed Web of Science ®Google Scholar
• Holman RR Cull CA Turner RC A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44) Diabetes Care 1999 22 6 960 964 10372249
   PubMed Web of Science ®Google Scholar
• Campbell RK Rationale for dipeptidyl peptidase 4 inhibitors: A new class of oral agents for the treatment of type 2 diabetes mellitus Ann Pharmacother 2007 41 1 51 60 17190843
   PubMed Web of Science ®Google Scholar
• Amori RE Lau J Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 2007 298 2 194 206 17622601
   PubMed Web of Science ®Google Scholar
• Scirica BM Bhatt DL Braunwald E Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 369 14 1317 1326 23992601
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [homepage on the Internet] Information for Healthcare Professionals – Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet) Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm Accessed October 5, 2009
   Google Scholar
• Merck – Highlights of prescribing information: Januvia [homepage on the Internet] Available from: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf Accessed December 1, 2013
   Google Scholar
• Bergman AJ Cote J Yi B Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor Diabetes Care 2007 30 7 1862 1864 17468348
   PubMed Web of Science ®Google Scholar
• Clar C Gill JA Court R Waugh N Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes BMJ Open 2012 2 5 pii:e001007
   Web of Science ®Google Scholar
• Vasilakou D Karagiannis T Athanasiadou E Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis Ann Intern Med 2013 159 4 262 274 24026259
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [homepage on the Internet] FDA News Release: FDA approves Invokana to treat type 2 diabetes 3 2013 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm Accessed May 22, 2014
   Google Scholar
• US Food and Drug Administration [homepage on the Internet] FDA News Release: FDA approves Farxiga to treat type 2 diabetes 1 2014 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm Accessed May 22, 2014
   Google Scholar
• Rosenstock J Aggarwal N Polidori D Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 2012 35 6 1232 1238 22492586
   PubMed Web of Science ®Google Scholar
• Schernthaner G Gross JL Rosenstock J Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Diabetes Care 2013 36 9 2508 2515 23564919
   PubMed Web of Science ®Google Scholar
• Cefalu WT Leiter LA Yoon KH Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 2013 382 9896 941 950 23850055
   PubMed Web of Science ®Google Scholar
• Nyirjesy P Zhao Y Ways K Usiskin K Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor Curr Med Res Opin 2012 28 7 1173 1178 22632452
   PubMed Web of Science ®Google Scholar
• Musso G Gambino R Cassader M Pagano G A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials Ann Med 2012 44 4 375 393 21495788
   PubMed Web of Science ®Google Scholar
• Nauck MA Niedereichholz U Ettler R Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am J Physiol 1997 273 5 Pt1 E981 E988 9374685
   PubMedGoogle Scholar
• Koliaki C Doupis J Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus Diabetes Ther 2011 2 2 101 121 22127804
   PubMedGoogle Scholar
• DeFronzo RA Ratner RE Han J Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 5 1092 1100 15855572
   PubMed Web of Science ®Google Scholar
• Buse JB Henry RR Han J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004 27 11 2628 2635 15504997
   PubMed Web of Science ®Google Scholar
• Moretto TJ Milton DR Ridge TD Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 2008 30 8 1448 1460 18803987
   PubMed Web of Science ®Google Scholar
• Buse JB Nauck M Forst T Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 2013 381 9861 117 124 23141817
   PubMed Web of Science ®Google Scholar
• Fineman MS Shen LZ Taylor K Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes Diabetes Metab Res Rev 2004 20 5 411 417 15343588
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [homepage on the Internet] Postmarket drug safety information for patients and providers. Information for healthcare professionals: Exenatide (marketed as Byetta) – 8/2008 update Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm Accessed December 4, 2013
   Google Scholar
• US Food and Drug Administration [homepage on the Internet] MedWatch. The FDA Safety Information and Adverse Event Reporting Program: Safety Information – Byetta (exenatide) – Renal Failure Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm Accessed December 04, 2013
   Google Scholar
• Kong MF Stubbs TA King P The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM Diabetologia 1998 41 5 577 583 9628276
   PubMed Web of Science ®Google Scholar
• Fineman MS Koda JE Shen LZ The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes Metabolism 2002 51 5 636 641 11979398
   PubMed Web of Science ®Google Scholar
• Hollander PA Levy P Fineman MS Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial Diabetes Care 2003 26 3 784 790 12610038
   PubMed Web of Science ®Google Scholar
• Palumbo PJ The case for insulin treatment early in type 2 diabetes Cleve Clin J Med 2004 71 5 385 394 15195774
   PubMed Web of Science ®Google Scholar
• Reza M Taylor CD Towse K Insulin improves well-being for selected elderly type 2 diabetic subjects Diabetes Res Clin Pract 2002 55 3 201 207 11850096
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 6 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• Rodbard HW Jellinger PS Davidson JA Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control Endocr Pract 2009 15 6 540 559 19858063
   PubMed Web of Science ®Google Scholar
• Horvath K Jeitler K Berghold A Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus Cochrane Database Syst Rev 2007 2 CD005613 17443605
   PubMed Web of Science ®Google Scholar
• Garber AJ Clauson P Pedersen CB Kolendorf K Lower risk of hypoglycemia with insulin detemir than with neutral protamine Hagedorn insulin in older persons with type 2 diabetes: A pooled analysis of phase III trials J Am Geriatr Soc 2007 55 11 1735 1740 17979896
   PubMed Web of Science ®Google Scholar
• Hermansen K Davies M Derezinski T A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes Diabetes Care 2006 29 6 1269 1274 16732007
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2009 32 1 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Ng JM Cooke M Bhandari S The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease Diabetes Care 2010 33 11 2310 2313 20798337
   PubMed Web of Science ®Google Scholar
• Young MJ Boulton AJ MacLeod AF A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population Diabetologia 1993 36 2 150 154 8458529
   PubMed Web of Science ®Google Scholar
• Aronow WS Fleg JL Pepine CJ ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Circulation 2011 123 21 2434 2506 21518977
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002 360 9356 7 22 12114036
   PubMed Web of Science ®Google Scholar
• Howard BV Howard WJ The compelling case for smoking cessation in diabetics Circulation 1990 82 1 299 301 2364516
   PubMed Web of Science ®Google Scholar
• No authors listed Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration BMJ 1994 308 6921 81 106 8298418
   PubMed Web of Science ®Google Scholar
• Hebert LE Scherr PA Bienias JL Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch Neurol 2003 60 8 1119 1122 12925369
   PubMed Web of Science ®Google Scholar
• Lustman PJ Clouse RE Treatment of depression in diabetes: impact on mood and medical outcome J Psychosom Res 2002 53 4 917 924 12377304
   PubMed Web of Science ®Google Scholar
• Lustman PJ Freedland KE Griffith LS Predicting response to cognitive behavior therapy of depression in type 2 diabetes Gen Hosp Psychiatry 1998 20 5 302 306 9788030
   PubMed Web of Science ®Google Scholar